OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Friday, July 25th WNEA, MGRN, GNAU, EPCT, PILL, CNEX

Jul 25, 2008 (M2 PRESSWIRE via COMTEX) -- WNEA | Quote | Chart | News | PowerRating -- Our Stocks to Watch today include Wind Energy America Inc. (OTCBB: WNEA), Monogram Energy Inc. (OTC: MGRN), General Automotive Co. (OTCBB: GNAU), EpiCept Corp. (Nasdaq: EPCT), ProxyMed Inc./MedAvant Healthcare Solutions (Nasdaq: PILL), Cannon Exploration Inc. (OTC: CNEX)

Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.

WIND ENERGY AMERICA INCORPORATED (OTCBB: WNEA)

Detailed Quote: www.otcpicks.com/quotes/WNEA.php

Company Profile: www.otcpicks.com/wind-energy-america/wind-energy-america-2.htm

Wind Energy America Inc. develops and operates wind energy projects in the Great Plains and the Midwest, regions known for their high quality wind energy resources. The Company owns interests in three wind farms: Shaokatan Hills LLC, Lakota Ridge LLC and CHI Energy. At present, WNEA owns a developer's stake and a minimal interest producing negligible cash flow in these wind farms. Over the next two years the developer's stake will begin producing significant cash flow from these projects. The three wind farms together contain 79 modern wind turbines and have a total rated capacity of 53.5 megawatts (MW). They are collectively generating approximately 160 million kilowatt hours (kWh) of electricity annually. In addition to these properties, the Company owns a 3 percent equity interest in Averill Wind LLC, a 10 MW wind farm being developed near Fargo, N.D., another region favorable for wind power energy.

WNEA News:

July 24 - Wind Energy America Inc. Engages CoreVentures Renewable Fuels

Wind Energy America Inc. (OTCBB: WNEA | Quote | Chart | News | PowerRating) has entered into an agreement with CoreVentures Renewable Fuels a privately owned renewable energy firm that specializes in project management and financing of renewable energy projects.

Joe Anderson, a partner at CoreVentures Renewable Fuels, former broker with Merrill Lynch, and a veteran at financing wind and other renewable energy projects had this to say: "We are excited about the opportunity to be working with Wind Energy America and see an almost unlimited potential for growth."

The majority shareholder of CoreVentures is CorVal Group, Inc. CorVal Group, Inc. is the holding company for seven independent companies in the construction, engineering & facilities industry. Most notable among them is NewMech Companies Inc., an 85 year old family owned business that employs over 600 people and has completed over $250 million in renewable energy projects.

Darrel Kluge CEO of Wind Energy America commented "Joe actually played an integral role in the financing of our Lakota Ridge, Shaokatan Hills and CHI wind farms almost ten years ago. We are fortunate to be gaining the benefit of his intuitive understanding of our business and what it takes to get projects completed."

MONOGRAM ENERGY INCORPORATED (OTC: MGRN | Quote | Chart | News | PowerRating) "Up 12.68% in morning trading"

Detailed Quote: www.otcpicks.com/quotes/MGRN.php

Company Profile: www.otcpicks.com/monogram-energy/monogram-energy.htm

Monogram Energy, Inc. is an independent energy company engaged in the acquisition, development, and exploitation of oil and gas properties. The company specializes in acquiring oil & gas leases with proven reserves that have the potential for increased production.

MGRN News:

July 25 - Monogram Energy, Inc. to Test New Production Fluid

Monogram Energy, Inc. (OTC: MGRN | Quote | Chart | News | PowerRating) announced that it will begin testing in its wells an environmentally safe production fluid. Preliminary tests show that this fluid is extremely stable, highly soluble in water, and extremely surface active. This surface activity makes it an extremely powerful water wetting agent, and it is this characteristic that accounts for its ability to efficiently and rapidly displace oil from solid surfaces. Should this new fluid react as the Company expects, it could double the production of each well.

Mr. Billy King, Chief Executive Officer of Monogram Energy, Inc., stated, "We are very excited about the potential for enhanced oil recovery that we can possibly achieve with the use of this product."

Mr. King became interested in the production of oil & gas during his ten years of employment as an attorney for the Halliburton Company, and with his representation of independent oil companies during his years as a private practitioner. Monogram Energy's goal is to maintain a high risk/reward profile, thereby enabling them to return the most value to its shareholders.

GENERAL AUTOMOTIVE COMPANY (OTCBB: GNAU)

Detailed Quote: http://www.otcpicks.com/quotes/GNAU.php

Company Profile: http://www.otcpicks.com/general-automotive/general-automotive-2.htm

General Automotive Company ("GAC") is a provider of original equipment and aftermarket automotive parts, mobile electronics, and related automotive products at multiple levels of distribution throughout the United States and internationally. Through its two wholly owned subsidiaries, Global Parts Direct and OE Source, the company focuses its efforts on utilizing its relationships with manufacturers in China, Korea and Japan to bring state-of-the-art automotive parts, accessories and products to automobile manufacturers and major parts distributors in the U.S. For more information on GAC and its products, visit www.generalautomotive.com.

GNAU News:

July 24 - General Automotive Announces Joint Venture to Develop and Market Advanced Fuel Cell Technology

* Partners with SenCer to Commercialize Breakthrough Approach for Powering Vehicles

* Additional Goal of Developing Next-Generation Oxygen Sensors

General Automotive Company (OTCBB: GNAU | Quote | Chart | News | PowerRating) ("GA"), a global provider of parts, accessories and advanced technology for the automotive industry, today announced a joint venture with SenCer Inc. to develop, commercialize and market SenCer's groundbreaking UltraTemp ceramic composite materials for accelerating the development of energy-efficient, environmentally friendly fuel cell technologies. The joint venture will also advance the development of next-generation oxygen sensors, which represent a significant part of GA's current business.

A Rochester, NY-based research firm known for its engineering expertise in advanced ceramic systems, SenCer has developed a series of next-generation ceramic fiber/ ceramic matrix composite materials with a wide variety of applications, including fuel cell stacks for powering automotive engines. The goal of the joint venture will be to develop a series of prototypes that will significantly advance the process of commercializing and, ultimately, mass producing fuel cells.

GA President and CEO Joseph DeFrancisci commented, "Hydrogen-powered fuel cells are widely viewed as a potential solution for higher energy prices and environmentally damaging emissions. The automotive sector, in particular, stands to reap tremendous benefits from this emerging technology as the engineering challenges that have confronted the industry to date are solved.

"SenCer's groundbreaking technology solves the two most persistent problems in fuel cell design - cost and durability - by replacing expensive platinum conductors with co-fired proprietary ceramic conductive layers. This is a breakthrough approach, and we are pleased to position GA at the forefront of this important effort through our joint venture with SenCer, which over the last 10 years has provided research and core ceramic materials to some of the leading developers of solid oxide fuel cells (SOFC).

"Additionally, the joint venture offers GA important benefits in the short term since SenCer's ceramic composite technology is also key to the design of next-generation oxygen sensors, which constitute an important revenue stream for GA today."

David Burt, President of SenCer and Chief Technology Officer of the new joint venture, stated, "We're very excited about the opportunity to partner with GA, whose business start-up and marketing capabilities will be key ingredients to our success. SenCer has taken a different direction to solving problems in fuel cell design by developing our UltraTemp Ceramic Composite as a support system for conductive ceramic layers. Our proprietary system is field-proven to bond multiple layers for long life and at low cost at temperatures almost twice that of conventional fuel cells. In addition we have a system that can operate at temperatures much lower than traditional SOFCs, thereby providing even longer life."

Mr. DeFrancisci concluded, "By combining SenCer's breakthrough technology with GA's business know-how and extensive industry contacts, we believe we can have a real impact on advancing the development and deployment of automotive fuel cell technology and on the design of more sophisticated oxygen sensors to help maximize fuel economy and minimize exhaust emissions. Cost-effective and durable fuel cell systems can provide an answer to some of the most pressing global problems, and our joint venture will help realize the tremendous potential of this field."

ABOUT SENCER INC.

Established in 1996, SenCer Inc. is a technology research firm that has developed a ceramic composite material, UltraTemp, with remarkable thermal properties and bonding capabilities. The new technology has applications in oxygen sensing (automotive and medical markets); oxygen generation (aluminum - inert anodes, gas generation, medical); and power generation (fuel cell technology). SenCer has been a behind-the-scenes player in many developments using ceramic composites. It maintains a 20,000 square foot manufacturing facility in Penn Yan, NY.

EPICEPT CORPORATION (NASDAQ: EPCT | Quote | Chart | News | PowerRating) "Up 186.67% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/EPCT.php

EpiCept Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for the treatment of cancer and pain. The company's lead oncology product candidate is Ceplene, which is used for the treatment of acute myeloid leukemia. Its cancer product portfolio includes Azixa, a Phase II clinical trial product to treat the patients with primary glioblastoma and melanoma that has metastasized to the brain and non-small-cell lung cancer that has spread to the brain; and EPC2407, a Phase I clinical trial completed oncology product candidate for the treatment of patients with advanced solid tumors and lymphomas. The company's pain product portfolio comprises EpiCept NP-1, a prescription topical analgesic cream for the long-term relief of peripheral neuropathies; LidoPAIN BP, a prescription analgesic non-sterile patch to provide sustained topical delivery of lidocaine for the treatment of acute or recurrent lower back pain; and LidoPAIN SP, a sterile prescription analgesic patch designed to provide sustained topical delivery of lidocaine to a post-surgical or post-traumatic sutured wound. It has strategic alliances with Endo Pharmaceuticals, Inc.; Myriad Genetics, Inc.; DURECT Corporation; Adolor Corporation; Epitome Pharmaceuticals Limited; and Shire Biochem, Inc. The company was founded in 1993 and is based in Tarrytown, New York.

EPCT News:

July 25 - Ceplene Receives Positive European Opinion for Approval From CHMP

* Marketing Authorization Normally Anticipated within 67 Days in the EU

* Conference Call to be Held July 28 at 9:00 a.m. Eastern Time

EpiCept Corporation (Nasdaq: EPCT | Quote | Chart | News | PowerRating) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion regarding the marketing authorization for Ceplene (histamine dihydrochloride), for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. Ceplene is to be administered in conjunction with low-dose interleukin-2 (IL-2). This positive opinion was issued following a request made by EpiCept to have the initial negative opinion of March 2008 re-examined by the CHMP. Ceplene has been designated as an orphan medicinal product, and as such is entitled to 10 years of marketing exclusivity in the EU.

EpiCept attended an oral explanation hearing at the CHMP's plenary meeting on July 22, 2008. Following this oral explanation, the CHMP recommended that Ceplene be granted a full marketing authorization under the provision of Exceptional Circumstances.

As part of granting of the marketing authorization under Exceptional Circumstances, EpiCept has agreed to perform two post-approval clinical studies. One of the studies seeks to further elucidate the clinical pharmacology of Ceplene by assessing certain biomarkers in AML patients in first remission. The other study will assess the effect of Ceplene/IL-2 on the development of minimal residual disease in the same patient population. EpiCept is entitled to seek further guidance on the design of such studies from the EMEA through the protocol assistance procedure.

"We are thrilled with the positive opinion reached by the CHMP and are pleased by the overwhelming support for Ceplene we received from key opinion leaders in hematology across Europe during this successful re-examination effort," stated Jack Talley, President and CEO of EpiCept. "Ceplene, in conjunction with IL-2, is the first therapy shown to significantly prolong leukemia-free survival and prevent relapse in AML patients in first remission."

The CHMP's recommendation will now be forwarded to the European Commission for issuing a marketing authorization in the form of a Commission Decision, which normally occurs within 67 days. The marketing authorization with unified clinical usage for Ceplene granted under the Centralized Procedure will be valid for the entire European Union as well as in Iceland, Liechtenstein and Norway.

"We are highly optimistic about the commercial prospects for Ceplene and we intend to pursue its commercial introduction as expeditiously as possible," continued Mr. Talley. "We are evaluating all of our strategic options for the marketing of Ceplene, and will continue to work towards realizing the drug's potential to fulfill an important unmet medical need for AML patients in Europe."

Conference Call

EpiCept announced that it will host a conference call to discuss this opinion and the Ceplene program on Monday, July 28, 2008 at 9:00 a.m. Eastern Daylight Time.

To listen to the conference call, please dial:

(877) 494-5472 (United States and Canada) (706) 758-9407 (International) The access code for the call is 57724791

A web cast of the conference can be accessed at www.epicept.com. The webcast will be archived for 90 days.

A playback of the call will be available for one week and may be accessed by dialing:

(800) 642-1687 (United States and Canada) (706) 645-9291 (International) Please reference reservation number 57724791

ABOUT ACUTE MYELOID LEUKEMIA (AML) AML is the most common type of leukemia in adults. There are approximately 40,000 AML patients in the EU, with 16,000 new cases occurring each year. Once diagnosed with AML, patients are typically treated with induction chemotherapy and consolidation therapy, with the majority achieving complete remission. However, about 75-80% of patients who achieve first remission will relapse, with the median time in remission before relapse being only 12 months with current treatments. Less than 5% of relapsed patients survive long term.

ABOUT CEPLENE

Ceplene is EpiCept's compound for the treatment of AML. Ceplene is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene reduces formation of oxygen radicals from phagocytes, inhibiting NADPH oxidase and protecting IL-2-activated NK-cells and T-cells.

PROXYMED INCORPORATED (NASDAQ: PILL | Quote | Chart | News | PowerRating) "Up 28.25% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/PILL.php

ProxyMed, Inc., doing business as MedAvant Healthcare Solutions, is an information technology company that facilitates the exchange of medical claim and clinical information among doctors, hospitals, medical laboratories, and insurance payers. It connects payers with providers in a real-time environment for the purpose of transparently messaging administrative, financial, and clinical information. The company offers products and services to process healthcare transactions, including claims, ERA, eligibility, claims status, referral authorization, and encounters. Its claims processing services include real-time processing; myMedAvant, a real-time Web portal; electronic attachments to claims possible; "Front door" pre-adjudication services; and same session claims processing. ProxyMed has strategic partnership with Bloodhound and The Sentinel Group. The company was founded in 1987 and is headquartered in Norcross, Georgia.

PILL News:

July 24 - MedAvant Wins Interim Approval From Bankruptcy Court for $2.9 Million in New Financing to Support Ordinary Course of Business in Chapter 11

Court Also Approves Motions to Pay Employees, Rebates and Critical Vendors

MedAvant Healthcare Solutions (Nasdaq: PILL | Quote | Chart | News | PowerRating) (MedAvant), a leader in healthcare technology and transaction services, announced that the United States Bankruptcy Court Judge presiding over its chapter 11 case in Delaware approved all of the initial motions presented at its first hearings important to the continued normal operations of the Company. Among the motions approved by the Court on an interim basis include the debtor-in-possession financing commitment of $2.9 million in new liquidity by its senior lender Laurus Master Fund, Ltd. This was done to support the Company's business operations during the chapter 11 case. In addition, the Court approved the Company's motion to pay employee wages/benefits, honor its customer rebate programs - both pre-petition balances and post-petition accruals - and to pay certain critical vendors.

"We are very pleased with the Court's rulings today and believe that they are important steps forward in our ongoing efforts to build a new, stronger company," said Peter Fleming, MedAvant interim Chief Executive Officer. "With the approval of all of our motions for new financing and to continue normal operations, our employees, our partners, and our customers will see nothing but a positive difference in our day-to-day business. We believe the judge's approval underscores the fundamental soundness of our restructuring strategies."

The Company filed for chapter 11 protection on July 23 in order to address its debt burdens through a sale and restructuring process. As previously announced, the Company has agreed to sell substantially all its business to Marlin Equity Partners, subject to higher and better bids at an auction to be conducted under section 363 of the Bankruptcy Code. The Bankruptcy Court will hear the Company's motion for approval of the bid procedures (including the setting of the bid and auction schedule) on August 4. The Company is requesting that initial bids be submitted by September 2 and that the auction itself be held on September 3 at the offices of its Delaware bankruptcy counsel Young, Conaway, Stargatt & Taylor. The Company's lead bankruptcy counsel, Michael P. Richman, of Foley & Lardner LLP in New York, told the Court today that the Company expects there to be competitive bidding based upon expressions of interest received from a number of parties both before and since the chapter 11 filing.

ABOUT MEDAVANT HEALTHCARE SOLUTIONS

MedAvant is a national connectivity network that connects payers with providers in a real-time environment for the purpose of transparently messaging administrative, financial and clinical information in order to lower total administrative costs, improve payer, provider and member relationships, and to ultimately improve clinical outcomes.

For more information, visit www.medavanthealth.com. MedAvant is a trade name of ProxyMed, Inc.

CANNON EXPLORATION INCORPORATED (OTC: CNEX | Quote | Chart | News | PowerRating) "Up 40.00% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/CNEX.php

Cannon Exploration is positioning itself to emerge as a pre-eminent resource exploration company in the North American mining industry, and particularly properties located in preferred mining districts in Canada.

CNEX News:

July 24 - Cannon Exploration Inc. Announces Acquisition

Exercises Option Agreement for up to 100% Ownership of "The Queen Alexandra" Gold Mine

Cannon Exploration Inc. (OTC: CNEX | Quote | Chart | News | PowerRating) announced that it has exercised its option to acquire 100% ownership of The Queen Alexandra Mine, located outside of Dryden, in Northern Ontario, Canada, having fully satisfied their requirements relating to the due diligence and initial earn in.

The Queen Alexandra Mine has known gold values, having produced gold in the past. Based on the historical data available, a recent geophysical testing program, completed by Cannon Exploration, demonstrated a possible extension of the mineralized zone.

Cannon Exploration Inc. will now begin full exploration of the Queen Alexandra property.

More information and data will be released in the coming weeks as it becomes available.

ABOUT OTCPICKS.COM

OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com is being compensated twenty thousand restricted 144 shares from a third party for WNEA advertising and promotional services. OTCPicks is receiving twelve thousand shares from a third party (Windermere Capital Partners) for GNAU advertising and promotion services. OTCPicks.com has received fifty thousand free trading shares from a non-controlling third party (Microcap Management) for MGRN advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.

The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

Third Party Web Sites and Information:

OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.

CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index